DDInter1938 DDInter661
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition.
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib